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Objective: To determine late toxicity and quality of life (QoL) in patients with localized prostate cancer after high-
dose intensity-modulated radiotherapy (IMRT).
Patient and methods: This was a prospective study in patients with localized prostate adenocarcinoma who had
been treated by IMRT (76 Gy) between February and November 2006. Physicians scored acute and late toxicity
using the Common Terminology Criteria for Adverse Events (version 3.0). Patients completed cancer and prostate-
specific QoL questionnaires (EORTC QLQ-C30 and QLQ-PR25) before IMRT (baseline) and at 2, 6, 18 and 54 months.
Result: Data were available for 38 patients (median age, 73 years) (18% low risk; 60% intermediate risk; 32% high
risk). The incidence of urinary and gastrointestinal toxicity was respectively: immediately post IMRT: 36.8% and 23.7%
(grade 1), 5.3% and 5.3% (grade 2), 2.6% and 0% (grade 3); at 18 months: 23.7% and 10.3% (grade 1), 26.3% and
13.2% (grade 2), 0% and 2.6% (grade 3); at 54 months: 34.2% and 23.7% (grade 1), 5.3% and 15.8% (grade 2), 5.3%
and 0% (grade 3). At 54 months, significant worsening was reported by patients for 11/19 QoL items but the
worsening was clinically relevant (>10 points) for 7 items only: physical, role as well as social functioning, fatigue,
pain, dyspnoea and constipation. There was no significant difference between 54-month and baseline QoL scores
for global health, gastrointestinal symptoms, treatment-related symptoms and sexual function. However, there was
significant - but clinically non-relevant (<10 points) - worsening of urinary symptom.
Conclusion: High-dose IMRT to the prostate with accurate patient positioning did not induce any clinically relevant
worsening in late urinary and gastrointestinal QoL at 54 months. Impaired physical and role functioning may be
related to age and comorbidities.
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In patients with localized prostate cancer and a good
prognosis, the efficacy of external beam is similar to that
of surgery or brachytherapy [1-3]. Adjuvant hormonal
therapy is often offered to patients with an intermediate
or poor prognosis [3]. However, over recent years,
radiotherapy (RT) has seen major advances such as the
introduction of 3D conformal RT (3D-CRT) and, more* Correspondence: stephane.supiot@ico.unicancer.fr
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reproduction in any medium, provided the orrecently, intensity-modulated radiation therapy (IMRT)
and image-guided RT (IGRT) [4,5].The higher radiation
doses that can be delivered to the prostate by these new
techniques, whilst sparing at-risk organs, has improved
progression-free survival and reduced acute and late
toxicities [6-13].
Quality of life (QoL) is a key criterion in the choice of
treatment for early prostate cancer but is difficult to assess
despite the availability of validated questionnaires [14-16].
Studies tend to be retrospective [17]. Long-term QoL after
IMRT has received attention in a limited number of pro-
spective studies [18,19] even though adverse effects are
known to occur late (over 30 months) [20,21].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients’ characteristics
Characteristics n (%)
Age at diagnosis
≤ 65 ans 9 (24%)
65-80 ans 28 (74%)
≥ 80 ans 1 (2%)
Cardiovascular history 15 (39%)
Classification risk at diagnosis
low risk 17 (45%)
Intermediate risk 11 (29%)
High risk 10 (26%)
Cancer status at 54 months
Remission 29 (76%)
Biological relapse 9 (24%)
high risk 7 (18%)
intermediate risk 1 (2%)
low risk 1 (2%)
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http://www.ro-journal.com/content/8/1/53In 2006, we initiated a prospective study of the toxicity
and QoL associated with high-dose IMRT for localized
prostate cancer. Results for 18 months of follow-up have
been published [22]. We now describe longer term
results (54 months) to confirm good tolerance of this
treatment after a long-term follow-up.
Patients and methods
This prospective study was performed in the Radiother-
apy Department of the “Integrated Center of Oncology
René Gauducheau” and included all consecutive pa-
tients with localised prostate cancer who were eligible
for IMRT without nodal irradiation between February
and December 2006. Absence of lymph node invasion
was established by laparoscopic lymphadenectomy in
patients with a >10% risk of invasion according to
Partin’s tables [23]. Absence of bone metastases was
established by bone scintigraphy.
The 5-field IMRT technique delivering a dose of
76 Gy in 38 fractions to the prostate and delineation of
organ-at-risk contour limits and constraints have been
described in an earlier publication [22]. The percent
organ-at risk volume receiving 65 Gy (V65) was derived
from dose-volume histograms for bladder and rectal tis-
sue. Patient positioning was checked daily [24].
Patients at intermediate risk of relapse according to
D’Amico’s classification [1] received concurrent adju-
vant hormonal therapy with an LHRH analogue for 3 to
6 months. Treatment was continued for 2 to 3 years in
high-risk patients.
Physicians scored treatment toxicity (general, urinary,
gastrointestinal (GI) and sexual) using the Common
Terminology Criteria for Adverse Events (CTCAE) to-
xicity scale (version 3.0) immediately after IMRT (acute
toxicity) and at subsequent visits (6, 18 and 54 months).
Patients completed the core and prostate cancer-
specific modules of the EORTC QoL questionnaires
(QLQ-C30 version 3.0 and QLQ-PR25) at their pre-
treatment and post-treatment visits (months 2, 6, 18
and 54). Items were combined into several scales (from
1 to 100) according to EORTC rules. For the global
health and function scales, a high score signalled a be-
tter QoL; for the symptom scales, a high score was indi-
cative of a poorer QoL.
Changes in toxicity and QoL over time were analyzed
by the Wilcoxon signed-rank test. Correlations between
toxicity and clinical or dosimetric variables were sought
using the Mantel-Haenszel test for linear association
(categorical variables) or the Spearman correlation coef-
ficient (continuous variables). A difference from baseline
was considered statistically significant if the p value was
< 0.01 and clinically relevant if the difference was > 10
points, as per Osoba interpretation of EORTC criteria
[25-27]. Factors that might predict QoL were tested by theKruskal-Wallis test (categorical variables) or the Spearman
correlation coefficient (continuous variables).
Results
From February to November 2006, 55 consecutive pa-
tients with localized prostate cancer underwent IMRT.
The characteristics of the 38 patients with data for analysis
at 54 months are given in Table 1. The remaining 17 pa-
tients were broken down as follows: 5 deaths from causes
other than prostate cancer, one case of Alzheimer’s disease
and 3 cases of advanced cancer other than prostate cancer
(rectum, lung, Vater’s ampulla) precluding completion of
the questionnaires, 3 refusals to complete the question-
naire at 54 months, and 5 lost to follow-up.
Median age at baseline was 73 years (range 54–80).
Among the 55 patients, 25 (45.5%) had received hormo-
nal therapy: 4 for 3 months, 11 for 6 months, and 10 for
2 to 3 years. The characteristics of the 17 loss to follow-
up patients were very similar to those of the 38 analys-
able patients at 54 months in terms of median age (73),
initial D’Amico’s classification (47% low risk, 24% inter-
mediate and 29% high risk) and acute asthenia (59%
mostly grade 1 at 41%), urinary toxicity (53% grade 1
and 35% grade 2) and bowel toxicity (24% grade 1
and 12% grade 2). Among the 38 analysable patients, 29
(76.3%) were in remission for prostate cancer and 9
(23.7%) in biochemical relapse whilst on hormonal the-
rapy. Of these 9 patients, 7 (78%) were high-risk patients
according to D’Amico’s classification.
Immediately after IMRT, 60.5% (15/38) patients reported
asthenia (39.5% grade 1). Its incidence decreased to 26.3%
(10/38) by 6 months and 7.9% (3/38) by 18 months, but
rose to 36.8% (28.9% grade 1) by 54 months.
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http://www.ro-journal.com/content/8/1/53Physician-assessed urinary and GI toxicity over time is
shown in Figure 1. During the last IMRT sessions, most
patients suffered from urinary symptoms (52.6% grade 1;
42.1% grade 2), mainly from dysuria and increased urin-
ation frequency. Only one patient experienced grade 3
urinary toxicity and underwent placement of a tempor-
ary urinary catheter. Urinary toxicity resolved in 57.9%
patients within 6 months. In the other patients, urinary
toxicity was low grade (34.2% grade 1; 5.3% grade 2) ex-
cept for one case (2.6%) of grade 3 toxicity. The inci-
dence of urinary toxicity was highly similar at 6 and
18 months (42.1% and 50%, respectively) and remained
stable until 54 months (44.7%) (34.2% grade 1; 7.9%
grade 2) with one patient experiencing grade 3 toxicity.
This patient underwent transurethral resection of the
prostate (TURP) for dysuria with partial improvement of
symptoms.
The reported incidence of GI toxicity immediately
after IMRT was 50% (39.5% grade 1; 10.5% grade 2). The
main symptoms were grade 1 diarrhoea (23.7%), fla-
tulence (18% grade 1; 8% grade 2), grade 1 proctitis
(15.8%) and haemorrhoids (n = 4 (10.5%) with 2 patients
presenting slight rectal bleeding). The incidence de-
creased to 26.3% at 6 months, was 28.9% at 18 months,
but rose to 39.5% (26.3% grade 1; 13.2% grade 2; no
grade 3) at 54 months. At 54 months, diarrhoea was less
frequent (10.6%) but had increased to grade 2 in 2 pa-
tients (5.3%). Flatulence was quite common (21.1% grade
1; 2.6% grade 2). Grade 1 rectitis and haemorrhoids
affected 4 patients (10%) in each case.
Sexual function was not assessed in all patients at all
time points. Only 12/38 patients (31.6%) were sexually
active immediately after IMRT. Sexual dysfunction was
recorded in 24/38 (63.2%) of patients at 18 months and
25/38 (65.8%) patients at 54 months (64% grade 1; 12%
grade 2; 8% grade 3).
In an analysis of predictive factors for late toxicity at 54 -
months, acute toxicity was not predictive of general late
toxicity (p = 0.52) or sexual dysfunction (p = 0.13). How-





















Figure 1 Physician assessment of urinary and bowel toxicity.(p = 0.0094) and late GI toxicity (p = 0.0213). The overall
rectal wall was not a predictive factor for late GI toxicity
(p = 0.54) but the volume receiving 65 Gy (V65) or 60 Gy
(V60) was (Table 2). Neither the overall nor V65 bladder
wall volumes were predictive factors for late urinary to-
xicity (p = 0.93 and 0.99 respectively).
Results for patient-assessed QoL over time are illus-
trated in Figure 2 with data before treatment and at 2, 6,
18 and 54 months. There was no significant difference
between time-points in global health, cognitive function,
social or emotional functioning. Physical and role (i.e.
work and play activities) functioning were maintained
until 18 months but were decreased at 54 months (−10.1
points (p =0.0002) and-13.2 points (p = 0.003) respect-
ively). Symptom scores at 54 months revealed increased
fatigue (+14 points, p = 0.003), dyspnoea (+15.8 points,
p = 0.002) and pain (+16.2 points, p = 0.0004). Urinary
symptoms (dysuria, increased urination frequency, in-
continence, urinary retention and haematuria) worsened
at 2 months (+10 points, p = 0.0001) but then improved
with time. The urinary symptom score was significantly
higher at 54 months than immediately after IMRT but
this difference was not clinically relevant as it was <10
points. No significant difference was recorded at any
time in GI symptoms (diarrhoea, flatulence, rectitis, rec-
tal bleeding, haemorrhoids) nor in sexual function.
In an analysis of predictive factors for QoL, risk category
(D’Amico classification) was a predictive factor for global
health (p = 0.026). Hormonal treatment was not (p = 0.34).
Rectal wall volume (overall or V65) was not a predictive
factor for GI symptoms. However, the V65 bladder wall
volume was a predictive factor for urinary symptoms (p =
0.05). Overall bladder wall volume and risk category were
not (p = 0.37 and 0.25, respectively).
Discussion
In this 54-month prospective study of late toxicity and
QoL in prostate cancer patients treated by IMRT, no sig-
nificant difference of clinical relevance was observed be-






Table 2 Predictive factors of late toxicity
Toxicity Predictive factors p
General Acute toxicity NS
Urinary Acute toxicity 0.01
V65 bladder wall NS
V40 bladder wall NS
bladder wall volume NS
Bowel V65 rectal wall 0.04
V60 rectal wall 0.03
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Figure 2 Patient self-assessment of changes in quality of life over tim
with baseline (Wilcoxon signed rank test, p <0.05); * (in red) Statistically sig
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http://www.ro-journal.com/content/8/1/53QoL (global health, cognitive, social and emotional func-
tioning). However, in contrast to the 3-year data in the
Lips et al. study, worsening physical and role functioning
was observed at 54 months, which had not been present
at 18 months [18,22]. The worsening we observed might
be related to patient age. It may not necessarily be due
to the presence or absence of hormonal therapy, as has
been suggested [28].
We observed temporary impairment of QoL at 2 months
mainly due to urinary disorders but urinary symptom
scores improved thereafter [22]. The increase in score with
respect to baseline at 54 months was not clinically relevant.
According to the physician assessments, by 6 months,
57.9% of patients no longer experienced any urinary tox-
icity and the incidence remained relatively stable until 54 -
months (44.7%). According to the literature, the negative
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e (a) Functional scales, (b) Symptom scales. *Significant difference
nificant and clinically relevant difference (>10 points).
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http://www.ro-journal.com/content/8/1/5312 months post RT [16,29], there is no difference in QoL
due to urinary symptoms after IMRT without hormonal
therapy compared to baseline, and urinary disorders im-
pact less on QoL after IMRT than 3D-CRT [18,30].
At 54 months, patients reported significant and clinic-
ally relevant differences with respect to baseline in un-
specific symptoms such as pain, dyspnoea and fatigue
but no differences in prostate cancer-specific symptoms
(urinary and GI disorders). The incidence of urinary and
GI toxicity 54 months after 76 Gy IMRT in our study is
similar to the 5-year incidence after 70 Gy 3D-CRT in
the GETUG 06 trial [8]. Grade 2+ urinary toxicity oc-
curred in 10.5% of our patients versus 10% (70 Gy) and
17.5% (80 Gy) in the GETUG 06 trial; Grade 2+ GI tox-
icity occurred in 13.2% of our patients versus 14%
(70 Gy) and 19.5% (80 Gy) patients in the GETUG 06
trial [8]. Dose escalation without enhancing toxicity is
thus possible if IMRT is used instead of 3D-CRT. The
results of several other studies support this conclusion: a
16% incidence of urinary toxicity and 3% incidence of GI
toxicity (grade 2+) 10 years after 81 Gy IMRT, a 9% inci-
dence of grade 2 urinary toxicity and a 5% incidence of
grade 2 GI toxicity 3 years after 76 Gy IMRT, and no dif-
ference in urinary or GI toxicity between 78 Gy IMRT
and 70 Gy 3D-CRT [31-33].
There were no significant and clinically relevant differ-
ences in sexual function over time, in contrast to the ob-
servations of Lips et al., but our patient numbers were too
small for the assessment to be meaningful [18,34]. Re-
spondent numbers were lowest immediately after IMRT
(n = 12) and at 6 months (n = 12) (compared to n = 24 and
25 at 18 and 54 months, respectively), suggesting that re-
covery of sexual activity occurs only some time after treat-
ment. Assessment of sexual function should therefore
probably not be restricted to assessment of just erectile
dysfunction, the commonly used objective criterion, but
should also take psychological factors into consideration.
In addition, assessment can be beleaguered by the fact that
a decrease in libido is sometimes still a taboo subject that
the practitioner may have difficulty in bringing up with
some patients [35].
Like other teams, we were able to identify few factors
associated with late urinary and GI toxicity and QoL,
probably because we had little data available for analysis at
54 months [36]. The only predictive factor in our study
was acute toxicity. In particular, hormonal therapy was
not an adverse predictive factor for QoL in our study, con-
trary to recent findings [37]. In our initial analysis at 18 m,
ADT was associated with a worsened quality of life, espe-
cially dyspnea, insomnia, treatment related symptoms and
sexual functioning. At 54 m, only 9 patients out of 36 were
still receiving ADT. This small proportion of patients
probably explains why we were not able to identify an ad-
verse QoL impact from ADT. Furthermore, Pedersonet al. found that age was associated with GI toxicity and
whole-pelvic IMRT with genito-urinary toxicity at 41 -
months, and that rectal but not bladder dose constraints
were associated with toxicity [32]. However, such con-
straints, even though they are crucial in limiting acute tox-
icity, are difficult to establish because bladder and rectal
filling varies between sessions [38].
The strengths of our QoL study are its prospective de-
sign and long (4½ years) follow-up. A key methodological
aspect is the use of validated self-administered patient
questionnaires. However, an important shortcoming is the
small number of patients who completed the 54-month
questionnaire owing to the deaths (unrelated to prostate
cancer) or serious illnesses encountered in this aged popu-
lation. There was no control arm but the prospective de-
sign enabled comparisons with baseline.
Conclusion
In conclusion, the high precision of IMRT in the treat-
ment of localized prostate cancer enables dose escalation
without engendering unacceptable toxicity [39]. There
was no impairment of urinary, GI and sexual function
nor of overall QoL at 54 months post IMRT. Decreased
physical and role functioning were observed but may be
related to ageing and comorbidities.
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